The 12-rung ladder
Evidence accumulates on the lower rungs, a guideline body, regulator, or payer acts on one of the middle three, and the market responds on the rest. Forecasts are registered against the middle three, because those are the steps with a date and an author.
The twelve rungs
Formal recommendation change by a recognized guideline body: grade shift, new/retracted endorsement, population expansion/restriction.
Evidence emergence
New trial results, replications, subgroup analyses, novel mechanisms, or new indications enter the public record.
- Set new readouts and subgroup analyses beside the claims they touch
- Compare effect size and endpoint definitions with the competitors' trials
- Note the first qualifier changes in the new publications
The single-study effect fails to replicate, or a safety signal appears in longer follow-up.
Replication & strengthening
Independent confirmation, effect consistency across populations, endpoint coherence, and methodological rigor.
- Read the meta-analyses and confirmatory trials for whether the effect holds
- Judge whether the evidence now matches what this committee has previously required
- Design registry or observational studies for the endpoints still contested
Endpoints differ between studies, or the meta-analyses disagree, and no consensus forms.
Expert recognition & KOL convergence
Field-level interpretation shifts: review articles, conference narratives, advisory-board consensus, editorial positions.
- Brief the clinical experts before the guideline drafting panel convenes
- Put medical affairs effort on the contested qualifiers before the committee fixes its scope
- Watch consensus statements and reviews for the wording the authority will later use
Experts disagree on clinical relevance or on how the subgroup is defined, and the field does not converge.
Real-world confirmation
RWE accumulation, registry data, claims analyses, practice-pattern shifts, and post-market surveillance.
- Assemble the real-world and claims analyses on persistence and adherence
- Draft the P&T dossier responses and the health-economics case
- Note where routine practice has already diverged from the label
Trial efficacy does not show up as effectiveness in routine-care cohorts.
Guideline action
Formal recommendation change by a recognized guideline body: grade shift, new/retracted endorsement, population expansion/restriction.
- Submit public comment while the guideline's review window is open
- Prepare regional access leads for a change in recommendation grade, such as Category 1 to 2A
- Re-read formulary exposure against the draft recommendation
The committee defers, waiting for long-term outcomes or a class review.
Regulatory action
Label/indication change, approval action, REMS modification, or withdrawal by FDA, EMA, PMDA, Health Canada, etc.
- Prepare advisory committee briefing material on the contested indications and safety wording
- Weigh the chance of a label restriction, a REMS requirement, or a boxed warning
- Align FDA and EMA filings where their wording is starting to differ
The review raises an unresolved safety question or asks for post-marketing commitments.
Payer/coverage action
NCD, LCD, formulary change, step-therapy revision, or access expansion/restriction by CMS, MACs, or major commercial payers.
- File the formulary package with the dated evidence record attached
- Negotiate tier placement and step-therapy criteria before the final LCD or NCD posts
- Prepare the field reimbursement team's response material
The payer restricts coverage to a subpopulation or adds prior authorization despite guideline support.
Rungs 8–12: what follows the decision
Adoption, coverage in practice, revenue, repricing. These are the consequences a team plans against; no forecast is registered on them, and no recorded decision has reached them.
- Rung 8 · Institutional policy adoption. Hospital pathways, P&T formulary placements, protocols, and EHR order sets updated to match the decision.
- Rung 9 · Clinical adoption. Prescribing moves to match the new position, at different speeds in specialist, primary-care, academic, and community settings.
- Rung 10 · Commercial strategy adjustment. Promotional claims, field messaging, patient support, and contracting are redone against the new wording.
- Rung 11 · Market repricing. The asset's valuation and deal terms move once the decision is public; a diligence read done before it priced the asset on the old position.
- Rung 12 · Patient-access / outcome consequences. Time to treatment, patient eligibility, and the cost to a health system: these change last, and they are the reason the earlier rungs matter.
When the expected act does not come
A guideline update, label expansion, or coverage revision that does not arrive by the expected date is usually recorded as a non-event. Read against the ladder, it is a stall at a particular rung, and the rung says what is missing:
Replication fails or endpoints disagree
The pivotal effect does not replicate in independent cohorts, or the meta-analyses conflict.
Experts disagree
Key opinion leaders and specialty societies contest the endpoint's relevance or the population's definition, and the committee waits.
Practice diverges from the trial
The trial effect does not appear in registry cohorts, or discontinuation and adherence problems show up in practice.
The institution defers
The committee defers the review, the comment period is extended, or the authority asks for post-marketing commitments.
What a proposition on rung 5 looks like
The first registered record is a rung-5 proposition: NCCN lists sunvozertinib as a first-line option in EGFR exon 20 insertion NSCLC, by 2027-07-31, with its evidence cutoff, its baselines, and the rule that settles it.
- Payer/coverage action
No payer action on record (downstream target).
- Regulatory action
China's CDE accepts the first-line NDA and grants priority review
Supplemental NDA submitted to FDA; Breakthrough Therapy Designation granted
- Guideline action
NCCN lists the agent as a Category 2A subsequent-therapy option; not first line
FF-001 registered: 75% that NCCN lists it first line by 2027-07-31 · pending
- Real-world confirmation
No real-world evidence published on record.
- Expert recognition & KOL convergence
The ASCO Post reports the readout independently
Cancer Discovery commentary: more first-line options in rare EGFR-mutant NSCLC
- Replication & strengthening
Nothing recorded at this rung.
- Evidence emergence
WU-KONG28 phase 3 reads out: first-line use beats platinum doublet on progression-free survival
Primary publication in the New England Journal of Medicine